Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. Bristol Myers Squibb pulled off three of these buyouts in the final three months of 2023, spending a combined $23 billion, while AbbVie inked a pair of deals totaling $19 billion. With drugmakers navigating patent cliffs and the looming effects of the Inflation Reduction Act, they are scrambling for new potential blockbusters to replace those that are nearing sales declines. Despite this recent splurge, going the high-priced-acquisition route is not the best way for companies to optimize their portfolios, according to a McKinsey report.
Read the full article: For Biopharma M&A, the Best Returns Come from Small Deals: Analysts //
Source: https://www.fiercepharma.com/pharma/analysts-prescription-big-pharma-take-ma-small-doses